Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer

10.18632/oncotarget.8692

Saved in:

Bibliographic Details
Main Authors:	Bhattacharya B., Low S.H.H., Chong M.L., Chia D., Koh K.X., Sapari N.S., Kaye S., Hung H., Benoukraf T., Soong R.
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Article
Published:	2020
Subjects:	buparlisib endothelin endothelin 1 selumetinib transforming growth factor beta2 antineoplastic agent mitogen activated protein kinase kinase kinase phosphatidylinositol 3 kinase protein kinase inhibitor acquired resistance animal experiment animal model animal tissue antineoplastic activity Article cancer combination chemotherapy cancer resistance cell stimulation colorectal cancer controlled study cross resistance drug efficacy drug potentiation EDN1 gene gene overexpression gene silencing genome analysis HCT116 cell line human human cell IC50 in vitro study in vivo study male mouse nonhuman phenotype signal transduction TGFB2 gene animal antagonists and inhibitors colorectal tumor drug resistance drug screening HCT 116 cell line pathology physiology SCID mouse Animals Antineoplastic Combined Chemotherapy Protocols Colorectal Neoplasms Drug Resistance, Neoplasm Drug Synergism HCT116 Cells Humans MAP Kinase Kinase Kinases Mice Mice, SCID Phosphatidylinositol 3-Kinases Protein Kinase Inhibitors Xenograft Model Antitumor Assays
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/174090
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-174090
record_format	dspace
spelling	sg-nus-scholar.10635-1740902024-04-03T07:38:12Z Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer Bhattacharya B. Low S.H.H. Chong M.L. Chia D. Koh K.X. Sapari N.S. Kaye S. Hung H. Benoukraf T. Soong R. CANCER SCIENCE INSTITUTE OF SINGAPORE DEAN'S OFFICE (MEDICINE) PATHOLOGY buparlisib endothelin endothelin 1 selumetinib transforming growth factor beta2 antineoplastic agent mitogen activated protein kinase kinase kinase phosphatidylinositol 3 kinase protein kinase inhibitor acquired resistance animal experiment animal model animal tissue antineoplastic activity Article cancer combination chemotherapy cancer resistance cell stimulation colorectal cancer controlled study cross resistance drug efficacy drug potentiation EDN1 gene gene overexpression gene silencing genome analysis HCT116 cell line human human cell IC50 in vitro study in vivo study male mouse nonhuman phenotype signal transduction TGFB2 gene animal antagonists and inhibitors colorectal tumor drug potentiation drug resistance drug screening HCT 116 cell line pathology physiology SCID mouse Animals Antineoplastic Combined Chemotherapy Protocols Colorectal Neoplasms Drug Resistance, Neoplasm Drug Synergism HCT116 Cells Humans MAP Kinase Kinase Kinases Mice Mice, SCID Phosphatidylinositol 3-Kinases Protein Kinase Inhibitors Xenograft Model Antitumor Assays 10.18632/oncotarget.8692 Oncotarget 7 20 29187-29198 2020-09-03T10:27:48Z 2020-09-03T10:27:48Z 2016 Article Bhattacharya B., Low S.H.H., Chong M.L., Chia D., Koh K.X., Sapari N.S., Kaye S., Hung H., Benoukraf T., Soong R. (2016). Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer. Oncotarget 7 (20) : 29187-29198. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.8692 19492553 https://scholarbank.nus.edu.sg/handle/10635/174090 Unpaywall 20200831
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	buparlisib endothelin endothelin 1 selumetinib transforming growth factor beta2 antineoplastic agent mitogen activated protein kinase kinase kinase phosphatidylinositol 3 kinase protein kinase inhibitor acquired resistance animal experiment animal model animal tissue antineoplastic activity Article cancer combination chemotherapy cancer resistance cell stimulation colorectal cancer controlled study cross resistance drug efficacy drug potentiation EDN1 gene gene overexpression gene silencing genome analysis HCT116 cell line human human cell IC50 in vitro study in vivo study male mouse nonhuman phenotype signal transduction TGFB2 gene animal antagonists and inhibitors colorectal tumor drug potentiation drug resistance drug screening HCT 116 cell line pathology physiology SCID mouse Animals Antineoplastic Combined Chemotherapy Protocols Colorectal Neoplasms Drug Resistance, Neoplasm Drug Synergism HCT116 Cells Humans MAP Kinase Kinase Kinases Mice Mice, SCID Phosphatidylinositol 3-Kinases Protein Kinase Inhibitors Xenograft Model Antitumor Assays
spellingShingle	buparlisib endothelin endothelin 1 selumetinib transforming growth factor beta2 antineoplastic agent mitogen activated protein kinase kinase kinase phosphatidylinositol 3 kinase protein kinase inhibitor acquired resistance animal experiment animal model animal tissue antineoplastic activity Article cancer combination chemotherapy cancer resistance cell stimulation colorectal cancer controlled study cross resistance drug efficacy drug potentiation EDN1 gene gene overexpression gene silencing genome analysis HCT116 cell line human human cell IC50 in vitro study in vivo study male mouse nonhuman phenotype signal transduction TGFB2 gene animal antagonists and inhibitors colorectal tumor drug potentiation drug resistance drug screening HCT 116 cell line pathology physiology SCID mouse Animals Antineoplastic Combined Chemotherapy Protocols Colorectal Neoplasms Drug Resistance, Neoplasm Drug Synergism HCT116 Cells Humans MAP Kinase Kinase Kinases Mice Mice, SCID Phosphatidylinositol 3-Kinases Protein Kinase Inhibitors Xenograft Model Antitumor Assays Bhattacharya B. Low S.H.H. Chong M.L. Chia D. Koh K.X. Sapari N.S. Kaye S. Hung H. Benoukraf T. Soong R. Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer
description	10.18632/oncotarget.8692
author2	CANCER SCIENCE INSTITUTE OF SINGAPORE
author_facet	CANCER SCIENCE INSTITUTE OF SINGAPORE Bhattacharya B. Low S.H.H. Chong M.L. Chia D. Koh K.X. Sapari N.S. Kaye S. Hung H. Benoukraf T. Soong R.
format	Article
author	Bhattacharya B. Low S.H.H. Chong M.L. Chia D. Koh K.X. Sapari N.S. Kaye S. Hung H. Benoukraf T. Soong R.
author_sort	Bhattacharya B.
title	Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer
title_short	Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer
title_full	Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer
title_fullStr	Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer
title_full_unstemmed	Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer
title_sort	acquired resistance to combination treatment through loss of synergy with mek and pi3k inhibitors in colorectal cancer
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/174090
_version_	1795374318665859072

Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer

Similar Items